Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

At the IASLC 2026 World Conference on Lung Cancer (WCLC), sessions highlighted novel clinical trial findings and other notable developments that may impact thoracic oncology practice. In addition to key oral presentations on data that may move the needle in non–small cell lung cancer (NSCLC) and small cell lung cancer, the meeting featured plenty of poster sessions detailing key therapeutic considerations across multiple disciplines.

From advances in surgical modalities to novel strategies in nursing and pathology, here are some of the noteworthy multidisciplinary takeaways that emerged from the meeting.

How can consolidative ablation work in tandem with TKIs for oligo-residual disease?

In a real-world study assessing 294 patients with advanced NSCLC and oligio-residual disease at Shanghai Pulmonary Hospital, survival improved when combining consolidative ablation with third-generation EGFR tyrosine kinase inhibitors.¹

Data showed a median progression-free survival (PFS) of 31.6 months (95% CI, 25.0-not reached [NR]) with TKIs plus ablation vs 17.9 months (95% CI, 16.7-21.3) with TKIs alone (HR, 0.35; 95% CI, 0.25-0.48; P <.001). Investigators also noted lower rates of symptomatic progression in the combination arm (17%) vs the TKI monotherapy arm (31%).

Among patients who underwent a post-progression biopsy in the combination (n = 18) and monotherapy arms (n = 58), rates of on-target EGFR mutations were 0% vs 8.5%, respectively. Additionally, 16.7% vs 6.9% of patients in each group had MET amplification as the predominant resistance mechanism.

“Consolidative ablation plus third-generation EGFR-TKIs improves survival in patients [with] advanced EGFR-mutant NSCLC with oligo-residual disease, together with [an] acceptable safety profile,” lead investigator Shengxiang Ren, from the Department of Medical Oncology at Shanghai Pulmonary Hospital School of Medicine at Tongji University, wrote with coauthors in the poster.¹ “Ablation reshapes the pattern of tumor progression and alters the evolving molecular landscape of tumors; this combination strategy represent[s] a promising consolidative therapy option in this population.”

Does ctDNA MRD surveillance have real-world application in resectable NSCLC?

According to the investigators of the real-world observational NOTICE study (NCT04976296), minimal residual disease (MRD) has emerged as a robust prognostic biomarker following lung cancer, although its performance and the potential clinical benefit of MRD-guided intervention remain underexplored in a real-world setting.² They consequently analyzed 3419 peripheral blood samples from 864 patients with completely resected stage I to IIIA NSCLC to assess the value of dynamic ctDNA MRD surveillance in this treatment setting.

Data showed that 27.2% (n = 235/864) of patients had disease events, with a 3-year disease-free survival (DFS) rate of 67.9% for the overall cohort. Patients with MRD negativity per landmark analysis experienced superior DFS outcomes vs those with MRD positivity (HR, 0.37; 95% CI, 0.27-0.50); the negative predictive value (NPV) was 78.2%. Under pragmatic MRD monitoring, the HR was 0.14 (95% CI, 0.099-0.194), with a NPV of 87.2%. Among those with MRD positivity following pragmatic MRD testing, adjuvant therapy significantly increased the 2-year MRD-positive DFS rate vs observation (61.8% vs 44.9%; HR, 0.636; P = .018).

“In a real-world setting, MRD serves as an ideal prognostic biomarker, though its positive predictive value may be affected by perioperative therapies,” lead investigator Chen Huang, from Guangdong Lung Cancer Institute of Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, wrote with coauthors in the poster.² “Adjuvant [therapy] for longitudinal MRD-positive [populations] could reduce the risk of recurrence.”

How does maladaptive coping strategies impact quality of life in advanced lung cancer?

Investigators of the ENABLE SG trial, which evaluated a coaching-based palliative care intervention or patients with newly diagnosed advanced malignancies, presented data on coping styles and quality of life (QOL) among 45 patients with newly diagnosed advanced lung cancer.³ Using 3 validated self-report instruments in the Brief COPE tool for coping and FACIT-PAL instrument for QOL, the investigators’ findings demonstrated how maladaptive coping patterns may negatively impact QOL in this patient population.

Although overall QOL and coping strategies were comparable across genders and marital statuses, maladaptive coping demonstrated a moderate, significant negative correlation with QOL (rho = –0.496; P <.001) over problem-focused (rho = .218; P = .150) and emotion-focused strategies (rho = –0.085; P = .578).

“Maladaptive coping is significantly associated with poorer [QOL] in [patients] newly diagnosed with advanced lung cancer, independent of gender or marital status,” lead study investigator Ang Yun Lee, from the Division of Oncology Nursing at National University Cancer Institute in Singapore, wrote with coinvestigators.³ “Early screening for maladaptive coping at diagnosis should be integrated into routine oncology and palliative care practice, enabling timely psychological support for [patients with] newly diagnosed advanced lung cancer.”

References

1. Ren S, Yin J, Zheng X. Consolidative ablation plus third-generation EGFR-TKIs improves survival in advanced NSCLC patients with oligo-residual disease. Presented at: 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract PT1.09.02.
2. Huang C, Cui Q, Gao X, et al. Real-world evaluation of dynamic ct-DNA MRD surveillance in resectable NSCLC: the NOTICE study. Presented at: 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract PT1.06.03.
3. Lee AY, Tan AJQ, Yu K, et al. A descriptive study of quality of life and coping strategies in persons with recently diagnosed advanced lung cancer. Presented at: 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract P2.285.